Gut 55:374-379 doi:10.1136/gut.2005.074062
  • Liver disease

Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C

  1. M Diago1,
  2. G Castellano2,
  3. J García-Samaniego3,
  4. C Pérez1,
  5. I Fernández2,
  6. M Romero3,
  7. O L Iacono4,
  8. C García-Monzón5
  1. 1Section of Hepatology, University General Hospital, Valencia, Spain
  2. 2Service of Gastroenterology, University Hospital Doce de Octubre, Madrid, Spain
  3. 3Service of Gastroenterology, Hospital Carlos III, Madrid, Spain
  4. 4Gastroenterology Department, University of Palermo, Italy
  5. 5Liver Research Unit, University Hospital Santa Cristina, Madrid, Spain
  1. Correspondence to:
    Dr C García-Monzón
    Liver Research Unit, University Hospital Santa Cristina, Maestro Vives, 2, 28009-Madrid, Spain; cgarcia.hscr{at}
  • Accepted 16 August 2005
  • Revised 8 August 2005
  • Published Online First 8 September 2005


Background: Increased serum and intrahepatic interferon γ inducible protein 10 (IP-10) levels in patients with chronic hepatitis C (CHC) have been described.

Aim: To analyse the possible association of serum IP-10 levels with different outcomes to antiviral therapy.

Patients: A total of 137 CHC patients treated with peginterferon plus ribavirin.

Methods: Serum IP-10 levels were determined by enzyme linked immunosorbent assay before therapy, after 12 weeks of treatment, and 24 weeks after cessation of therapy. Variables significantly associated with a sustained virological response (SVR) on univariate analysis were included in a multivariate logistic regression model.

Results: Pretreatment serum IP-10 levels in patients with SVR were significantly lower than in non-responders (NR) (332.4 (222.1) v 476.8 (305.3) pg/ml, respectively; p = 0.004). Serum IP-10 concentrations significantly decreased in patients with SVR (pretreatment: 332.4 (222.1) pg/ml; post-treatment: 170.2 (140.1) pg/ml; p<0.001) but not in NR (pretreatment: 476.8 (305.3) pg/ml; post treatment: 387.3 (268.1) pg/ml; p = 0.06). By multivariate analysis, non-1 genotype (odds ratio (OR) 3.5 (95% confidence interval (CI) 1.1–10.4); p = 0.003) and low viral load at baseline (OR 0.34 (95% CI 0.14–0.79); p = 0.01) were independent predictors of SVR in all patients. When multivariate analysis was restricted to patients with genotype 1, only baseline viral load (OR 0.38 (95% CI 0.155–0.96); p = 0.04) and pretreatment serum IP-10 levels (OR 0.99 (95% CI 0.996–0.999); p = 0.03) were identified as predictive factors of SVR.

Conclusion: Pretreatment serum IP-10 behaves as a predictive factor of SVR to peginterferon plus ribavirin therapy in genotype 1 infected patients.


  • Published online first 8 September 2005

  • Conflict of interest: None declared.